2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
37
Lymphoma
37
Lymphoma, Follicular
33
Lymphoma, Large B-Cell, Diffuse
30
Lymphoma, Mantle-Cell
22
Lymphoma, B-Cell, Marginal Zone
13
Leukemia, Lymphocytic, Chronic, B-Cell
13
Waldenstrom Macroglobulinemia
9
Lymphoma, Large-Cell, Immunoblastic
9
Burkitt Lymphoma
9
Lymphoma, B-Cell
6
Lymphoma, Large-Cell, Anaplastic
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
2
Leukemia
2
Recurrence
1
Orbital lymphoma
1
Oncology Patients Receiving Chemotherapy
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, AIDS-Related
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Graft vs Host Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Interventions
Rituximab
9
Cyclophosphamide
8
fludarabine
5
dacetuzumab
5
blinatumomab
5
Brentuximab Vedotin
4
Bendamustine Hydrochloride
4
ibrutinib
3
fludarabine phosphate
3
Vincristine
3
Prednisone
3
Melphalan
3
Etoposide
3
Doxorubicin
3
tetulomab tetraxetan lu-177
2
ponatinib
2
cobomarsen
2
acalabrutinib
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Lutetium
2
Ifosfamide
2
Everolimus
2
Cytarabine
2
Carboplatin
2
Busulfan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphatic Diseases
×
ibritumomab tiuxetan
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts